Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy With Lenacapavir-containing Regimen.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 39737782.
- Also identified by DOI 10.1093/cid/ciae650.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lenacapavir is the first capsid inhibitor and its use is currently approved for multidrug-resistant human immunodeficiency virus-1 infection. We report that, despite the initial efficacy of a lenacapavir-containing regimen in patients with multidrug-resistant human immunodeficiency virus-2 viruses, virological suppression was not achieved after a year and most patients selected capsid drug resistance-associated mutations.
Medical subject headings
- HIV Infections
- HIV-2
- Salvage Therapy
- Mutation
- Anti-HIV Agents
- Capsid Proteins
- Selection, Genetic